RE:article
sl,
IMO this entire chit chat that everyone brings up re. "narrow label" is borne and lives in silliness...as best i know (read Adcom transcript and BCAN and???) surgery aka cystecotmy (or aka the blue light special) is the real general 1st line treatment and i believe it is as it has the best outcomes...so BCG is 2nd line (specialty front line for surgery unable, etc.) and key is this patients refuse surgery as a part of a process to get BCG...so IMO patient refusal of surgery (in all its shapes and sizes) is SOP and if this is what is labeled for MCNA i believe it is actually a label expansion as previous it was an option to BCG failure...and if iincludes the BCG component also it is really no harm no foul re. revenue..all you need is "informed consent" which IMO is mostly try it and if it don't work in 6 months we operate...
read adcom the bladder doc consultants were tremendously knowing and very good. (one was i believe the leading BCG and chemo bladder doc in the world to boot and his thumbs up for MCNA is more useful than all others).. sucks they had the TST B team there and sucks worse that neither the CEO or COO was fired on account of this failure but there you go